🔗 Share this article

As America proceeds with unprecedented revisions to its vaccination recommendations, a particular individual has surfaced unexpectedly: Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has zeroed in on alleged fatalities after Covid immunization in her brief time at the FDA.

Planned Shifts to Pediatric Immunization Program

Agency leaders planned to announce radical revisions to the childhood vaccination calendar recently, aligning the US with the Danish vaccine program, sources say – a significant shift that would place the US out of alignment with a large portion of the global community with no evidence for improved outcomes. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing some childhood immunization guidelines in the US in order to be more like the Danish model, a country with nationalized medicine and a population about the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has little discernible track record in drug development, regulation or administrative roles, which has been standard for previous heads of the CBER. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the CDER, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “grasp laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who ran CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those must be supervised,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major administrative element to the position, which manages in excess of 5,000 employees. “It’s a massive leadership role, if you do it right,” the former official said.

Official Statement and Contentious Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among regulatory chiefs on immunizations, a representative said that the “inquiries rely on flawed presumptions”.

“Her resume aligns with the duties of her position,” the spokesperson stated, pointing to the months Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a contentious rapid medication authorization process that apparently worried her former heads. “How are these drugs being selected for this fast-track system? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed oversight of all drugs, aside from vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if concerning, history, Howard said. She released a research paper using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership encompassed revising regulations for novel immunizations and ending “optional” immunizations, she remarked after the election on a online show. At the FDA, Høeg has allegedly suggested excluding teenage boys from getting Covid vaccinations.

“She is an complete ideologue who begins with her conclusions and reverse-engineers to fit the data in a highly misleading, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|